Oxford BioDynamics (LON:OBD) Sets New 1-Year Low – Here’s Why

Oxford BioDynamics Plc (LON:OBD) shares reached a new 52-week low during mid-day trading on Thursday . The company traded as low as GBX 0.15 and last traded at GBX 0.17, with a volume of 6221344 shares trading hands. The stock had previously closed at GBX 0.17.

Oxford BioDynamics Price Performance

The firm has a market capitalization of £7.34 million, a price-to-earnings ratio of -0.21 and a beta of 0.42. The business has a 50 day moving average of GBX 0.19 and a 200 day moving average of GBX 0.23. The company has a debt-to-equity ratio of 457.97, a current ratio of 0.88 and a quick ratio of 2.80.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.